Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 1;158(5&6):559-564.
doi: 10.4103/ijmr.ijmr_2634_22. Epub 2024 Jan 24.

A descriptive study of hepatitis C in people who inject drugs

Prakrithi Shivaprakash  1 , Vinit Patel  1   2 , Darshan Shadakshari  1 , Rahul Verma  1 , Lekhansh Shukla  1 , Jayant Mahadevan  1 , Arun Kandasamy  1 , Prabhat Kumar Chand  1 , Vivek Benegal  1 , Lakshmanan Sethuraman  1 , Priyamvada Sharma  3 , Pratima Murthy  1
Affiliations

A descriptive study of hepatitis C in people who inject drugs

Prakrithi Shivaprakash et al. Indian J Med Res. .

Abstract

Background objectives: The seroprevalence of the hepatitis C virus (HCV) in general population is higher than that of human immunodeficiency virus (HIV) in India. People who inject drugs (PWIDs) constitute a high-risk group for all blood-borne infections. Multiple behavioural surveillance surveys have provided a rich typology of HIV-infected PWIDs, but this information is missing for HCV infection. We describe awareness, transmission risk factors and the treatment continuum for HCV infection among PWID. We also report spatial clustering of HCV infection in PWIDs residing in Bengaluru.

Methods: Information from clinical records was collected and telephonic interviews of retrospectively identified PWIDs who received treatment at a tertiary-level addiction treatment facility between 2016 and 2021 were conducted.

Results: We identified 391 PWIDs; 220 (56.26%) received an anti-HCV antibody test (4 th Generation HCV-Tridot). Individuals reporting unsafe injection practices were more often tested than those who did not ( χ2 =44.9, df=1, P <0.01). Almost half of the tested and more than a quarter of the whole sample (109/220, 49.9%; 109/391, 27.9%) were seropositive for HCV infection. The projected seropositivity in this group was between 27.9 per cent (best case scenario, all untested assumed negative) and 71.6 per cent (worst case scenario, all untested assumed positive). Only a minority of participants interviewed were aware of HCV (27/183, 14.7%). HCV infection and its associated risk behaviour (PWID) were clustered in certain localities (Diggle and Chetwynd Test; P =0.001) in Bengaluru in the southern district of Karnataka.

Interpretation conclusions: Undetected HCV infection is common in PWIDs; awareness and treatment uptake is poor in this group. Spatial clustering of infections in a district shows transmission in close networks and provides opportunities for targeted interventions.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure
Figure
Study procedure. ICD, international classification of diseases; IDU, injecting drug use.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) Combating hepatitis B and C to reach elimination by 2030. Geneva, Switzerland: WHO Press; [accessed on July 05, 2023]. Available from: https://apps.who.int/iris/bitstream/handle/10665/206453/WHO_HIV_2016.04_... .
    1. Ministry of Health and Family Welfare, Government of India. National Program for surveillance of viral Hepatitis. Seroprevalence of Hepatitis B and Hepatitis C (based on National Family Health Survey-4) factsheet 2021. [accessed on July 05, 2023]. Available from: https://nvhcp.mohfw.gov.in/common_libs/Approved%20factsheet_4_10_2021.pdf .
    1. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review. Lancet Glob Health. 2017;5:e1192–207. - PMC - PubMed
    1. Goel A, Seguy N, Aggarwal R. Burden of hepatitis C virus infection in India: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2019;34:321–9. - PubMed
    1. Ministry of Social Justice and Empowerment, Government of India. Magnitude of substance use in India ; 2019. [accessed on July 05, 2023]. Available from: https://socialjustice.gov.in/writereaddata/UploadFile/Survey%20Report636... .